Mesalazine Teva

Mesalazine, the active ingredient in Mesalazine Teva, is a 5‑aminosalicylic acid (5‑ASA) presented as an oral tablet for oral use. It reduces inflammation in the colon and is employed to manage ulcerative colitis and Crohn’s disease in adult patients. It is indicated for maintenance of remission and induction of response, offering a targeted anti‑inflammatory effect with minimal systemic absorption.

GNH USA supplies Mesalazine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global healthcare providers.

Mesalazine is a 5‑ASA agent used to treat inflammatory bowel disease by targeting colonic inflammation. - Ulcerative colitis: reduces colonic inflammation to induce and maintain remission. - Crohn's disease: alleviates intestinal inflammation, helping achieve clinical response. - Maintenance therapy: supports long‑term disease control with minimal systemic exposure.

Mesalazine may be associated with a range of adverse reactions, most of which are mild and reversible. Common Side Effects: - Nausea: mild stomach upset. - Headache: transient headache. - Diarrhea: loose stools. Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or breathing difficulty. - Hepatotoxicity: elevated liver enzymes or jaundice. - Kidney impairment: interstitial nephritis or reduced renal function.

Before initiating therapy, clinicians should consider several precautionary measures. - Monitor disease activity: assess clinical response regularly. - Assess renal function: check baseline and periodic kidney tests. - Evaluate liver enzymes: perform hepatic function tests before and during therapy. - Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mesalazine can interact with other medicines; some interactions require avoidance while others need monitoring. Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Sulfonamide antibiotics (e.g., trimethoprim‑sulfamethoxazole): heightened risk of hypersensitivity. - Live vaccines: may reduce vaccine efficacy. Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Azathioprine or 6‑mercaptopurine: potential for enhanced bone marrow suppression.